SCHEMBL17323643

SCHEMBL17323643

CC(C)C(=O)N1CCC1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.41
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
KMT2A Q03164 1/20 0.39
DPP4 P27487 8/20 0.38
SMN1; SMN2 Q16637 1/20 0.36
CHRNB2 P17787 1/20 0.36
CHRNA3 P32297 1/20 0.36
CHRNA4 P43681 1/20 0.36
CHRNB3 Q05901 1/20 0.36
CHRNA6 Q15825 1/20 0.36
GAA P10253 2/20 0.36
HPGD P15428 1/20 0.36
MAPT P10636 1/20 0.35
FAP Q12884 2/20 0.34
DPP7 Q9UHL4 2/20 0.34
PREP P48147 1/20 0.34
DPP8 Q6V1X1 1/20 0.34
DPP9 Q86TI2 1/20 0.34
LIPE Q05469 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9927075 0.87 GAA (0.46) DPP4GAAHPGDMAPTFAP
SCHEMBL1106509 0.87 GAA (0.46) DPP4GAAHPGDMAPTFAP
SCHEMBL17323644 0.87 GAA (0.46) DPP4GAAHPGDMAPTFAP
SCHEMBL15893914 0.86 PIK3CD (0.36) PIK3CDMEN1ALDH1A1KMT2ASMN1; SMN2
SCHEMBL4546663 0.85 HPGD (0.53) MEN1ALDH1A1KMT2ASMN1; SMN2GAA
SCHEMBL17323629 0.85 HPGD (0.53) MEN1ALDH1A1KMT2ASMN1; SMN2GAA
SCHEMBL17323635 0.85 HPGD (0.53) MEN1ALDH1A1KMT2ASMN1; SMN2GAA
SCHEMBL15893910 0.82 SMN1; SMN2 (0.43) PIK3CDSMN1; SMN2
SCHEMBL15893911 0.81 CHRNB2 (0.36) PIK3CDMEN1ALDH1A1KMT2ADPP4
SCHEMBL318016 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9663488-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2017-05-30 US disclosed
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals (NC), Inc. 2015-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO PIK3CD 4646/4885MEN1 511/4885ALDH1A1 289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.